Rapid Mixed-Mode SPE Method Development Using the Oasis® µElution Sorbent Selection Plate
Rapid Mixed-Mode SPE Method Development Using the Oasis® µElution Sorbent Selection Plate
Ce document est une note d’application et ne contient pas de section détaillée concernant l’expérimentation.
Abstract
This application demonstrates the fast and simple mixed-mode (MM) solid phase extraction (SPE) method development using the Oasis Method Development μElution Plate, which contains 4 sorbent chemistries (MCX, WAX, WCX, MAX), facilitating rapid screening in one experiment with only 2 protocols for the pharmaceuticals, abrocitinib, and enzalutamide.
Experimental
Table 1. Physiochemical properties of enzalutamide and abrocitinib pharmaceuticals.
Figure 1. Representative Oasis 2x4 Mixed-Mode (MM) SPE method development protocol used with the, Oasis Method Development 96-well µElution Plate. This simple, logical approach provides rapid evaluation of for MM sorbent chemistries (MCX, WAX, WCX, and MAX) for a diversity of analytes (acids, bases, and neutrals), which takes the complexity out of MM SPE method development.
Figure 2. Demonstration of Oasis mixed-mode SPE bioanalytical extraction performance of abrocitinib (Panel A), and enzalutamide (Panel B) using the Oasis 2x4 Mixed-Mode (MM) SPE method development protocol and Oasis Method Development 96-well µElution Plate. Best abrocitinib recovery (92%) was found in the neutral fraction (Elute 1) using the MCX sorbent, while best enzalutamide recovery (106%) was found using the MCX sorbent and the mixed-mode fraction (Elute 2).
Results and Discussion
The Oasis Method Development µElution Plate and starting protocols provide quick and easy mixed-mode SPE method development in one experiment, facilitating high analyte recovery, and selectivity (low matrix effects) from plasma.
Ordering Information
720008425, July 2024
